Math may help treat leukemiaJune 20th, 2008 - 12:33 pm ICT by ANI
Washington, June 20 (ANI): If your kid complains that his math homework is of no use in real life, convey him this simple message the subject can help cure leukemia.
In a new study that combined math and medicine, researchers have shown that patients with Chronic Myelogenous Leukemia (CML) may be cured of the disease with an optimally timed cancer vaccine, where the timing is determined based on their own immune response.
Published in the June 20 edition of the journal PLoS Computational Biology, University of Maryland associate professor of mathematics Doron Levy, Stanford Medical School physician and associate professor of medicine (hematology) Peter P. Lee, and Dr. Peter S. Kim, Ecole Superieure d’Electricite (Gif-sur-Yvette, France) describe their success in creating a mathematical model which predicts that anti-leukemia immune response in CML patients using the drug imatinib can be stimulated in a way that might provide a cure for the disease.
“By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient,” said Levy, of the University of Maryland Center for Scientific Computation and Mathematical Modeling.
“Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans, Levy added.
In the study, the researchers took into account the patient’s natural immune response in conjunction with the effects of imatinib, a drug that has been successful in putting CML patients into remission.
They wanted to see if they could develop a mathematical model, or set of rules, that would increase chances for long-term remission in individual patients.
Over four years, Lee’s laboratory collected data from CML patients, measuring the strength of each patient’s immune response, in the form of the numbers and the activity of the anti-leukemia T cells, at different times during imatinib therapy.
“Our results suggest that it is not only the drug that sends the leukemia into remission, it’s also the natural immune response. After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak. This typically happens well into the treatment, Levy said.
“Leukemia cells are still present, but in relatively low numbers that causes the immune response to wind down. Unfortunately, this is an ideal time for the cancer cells to develop drug resistance and render the therapy ineffective, Levy added.
The mathematical model suggests that the immune response of the patients should be boosted at the time when their immune response starts weakening. (ANI)
- Now, a one-two drug punch approach to KO a lethal cancer - Jun 08, 2009
- SC again asks Novartis to cut cancer drug price - Sep 12, 2012
- Combo of targeted drugs may prove more effective in leukemia fight - Oct 21, 2008
- Why don't you reduce cancer drug price, SC asks Novartis - Sep 11, 2012
- Arsenic could improve survival for leukaemia patients - Nov 12, 2010
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- Magnetic pulse therapy may help treat depression: Study - May 10, 2012
- Bioengineered protein may help fight leukemia - Feb 19, 2011
- Umbilical cord cells may be useful in arthritis treatment - Nov 16, 2010
- New study shows evidence of stem cells' pivotal role in cancer - Dec 22, 2010
- Key cause of chronic leukemia progression identified - Mar 05, 2010
- Biological agents could prevent Crohn's disease recurrence - Aug 06, 2010
- New one-off treatment may help cure rheumatoid arthritis - Apr 12, 2010
- Fish oil may hold key to leukaemia cure - Dec 23, 2011
Tags: biological data, cancer vaccine, chronic myelogenous leukemia, cml patients, cure leukemia, ecole superieure, gif sur yvette, imatinib, immune response, maryland center, math homework, mathematical model, mathematical modeling, plos computational biology, remission, school physician, scientific computation, simple message, stanford medical school, t cells